JPH04364119A - Bathing agent composition - Google Patents

Bathing agent composition

Info

Publication number
JPH04364119A
JPH04364119A JP16521191A JP16521191A JPH04364119A JP H04364119 A JPH04364119 A JP H04364119A JP 16521191 A JP16521191 A JP 16521191A JP 16521191 A JP16521191 A JP 16521191A JP H04364119 A JPH04364119 A JP H04364119A
Authority
JP
Japan
Prior art keywords
proteinase
agent composition
inorganic salt
sodium carbonate
bathing agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP16521191A
Inventor
Yasuhiro Yoshida
Original Assignee
Tsumura & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsumura & Co filed Critical Tsumura & Co
Priority to JP16521191A priority Critical patent/JPH04364119A/en
Publication of JPH04364119A publication Critical patent/JPH04364119A/en
Application status is Pending legal-status Critical

Links

Abstract

PURPOSE: To provide a bathing agent composition containing an alkaline inorganic salt and a proteinase, exhibiting slightly alkaline nature and excellent cleaning effect in dissolution, giving smoothing and refreshing feeling to the skin after bath and effective for the treatment of heat rashes, pimples, etc.
CONSTITUTION: The objective bathing agent composition contains (A) an alkaline inorganic salt such as sodium carbonate, borax, sodium metasilicate and sodium sulfate (especially preferably sodium carbonate) and (B) a proteinase such as pancreatin obtained from the pancreas of pig or cattle (especially preferably a proteinase originated from microorganism of the genus Bacillus) and exhibits pH 8.0-10.0 when dissolved in bath water. The concentration of the alkaline inorganic salt such as sodium carbonate is adjusted to 20-200ppm, preferably 30-150ppm and the content of the proteinase is preferably selected to ≥0.1wt.%.
COPYRIGHT: (C)1992,JPO&Japio
JP16521191A 1991-06-11 1991-06-11 Bathing agent composition Pending JPH04364119A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP16521191A JPH04364119A (en) 1991-06-11 1991-06-11 Bathing agent composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16521191A JPH04364119A (en) 1991-06-11 1991-06-11 Bathing agent composition

Publications (1)

Publication Number Publication Date
JPH04364119A true JPH04364119A (en) 1992-12-16

Family

ID=15807960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16521191A Pending JPH04364119A (en) 1991-06-11 1991-06-11 Bathing agent composition

Country Status (1)

Country Link
JP (1) JPH04364119A (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048775A1 (en) * 1997-02-12 1998-11-05 Johnson & Johnson Consumer Companies, Inc. Serine protease and topical retinoid compositions
FR2817475A1 (en) * 2000-12-04 2002-06-07 Rocher Yves Biolog Vegetale Use of a composition, comprises proteases and a retinol source to combat skin aging
JP2009292809A (en) * 2008-05-09 2009-12-17 Kracie Home Products Ltd Skin touch feeling improver and skin cosmetic compounded with the same, and method for improving skin touch feeling
JP2012514602A (en) * 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー Compositions and methods for eradication or reduction of Staphylococcus aureus which are in the compositions and methods as well as on the surface for the treatment or prevention of Staphylococcus aureus infection
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US8815233B2 (en) 1999-12-17 2014-08-26 Curemark Llc Method for treating pervasive development disorders
US8921054B2 (en) 2000-11-16 2014-12-30 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US9017665B2 (en) 2008-04-18 2015-04-28 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9023344B2 (en) 2008-03-13 2015-05-05 Curemark, Llc Method of treating toxemia
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US9345721B2 (en) 2005-08-30 2016-05-24 Curemark, Llc Use of lactulose in the treatment of autism
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048775A1 (en) * 1997-02-12 1998-11-05 Johnson & Johnson Consumer Companies, Inc. Serine protease and topical retinoid compositions
US9624525B2 (en) 1999-12-17 2017-04-18 Curemark, Llc Method for treating pervasive development disorders
US8815233B2 (en) 1999-12-17 2014-08-26 Curemark Llc Method for treating pervasive development disorders
US9624526B2 (en) 1999-12-17 2017-04-18 Curemark Llc Method for treating pervasive development disorders
US9233146B2 (en) 2000-08-14 2016-01-12 Curemark, Llc Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US9377459B2 (en) 2000-11-16 2016-06-28 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8921054B2 (en) 2000-11-16 2014-12-30 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US10209253B2 (en) 2000-11-16 2019-02-19 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
FR2817475A1 (en) * 2000-12-04 2002-06-07 Rocher Yves Biolog Vegetale Use of a composition, comprises proteases and a retinol source to combat skin aging
US9345721B2 (en) 2005-08-30 2016-05-24 Curemark, Llc Use of lactulose in the treatment of autism
US9925250B2 (en) 2008-03-13 2018-03-27 Curemark, Llc Method of treating proteinuria in pregnancy
US9023344B2 (en) 2008-03-13 2015-05-05 Curemark, Llc Method of treating toxemia
US9408895B2 (en) 2008-03-13 2016-08-09 Curemark, Llc Method of treating pregnancy-induced hypertension
US9687534B2 (en) 2008-04-18 2017-06-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9017665B2 (en) 2008-04-18 2015-04-28 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
JP2009292809A (en) * 2008-05-09 2009-12-17 Kracie Home Products Ltd Skin touch feeling improver and skin cosmetic compounded with the same, and method for improving skin touch feeling
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
US9687535B2 (en) 2008-10-03 2017-06-27 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
JP2015129135A (en) * 2009-01-06 2015-07-16 キュレロン リミテッド ライアビリティ カンパニー Compositions and methods for treatment or prevention of staphylococcus aureus infections, and compositions and methods for eradication or reduction of staphylococcus aureus on surfaces
US9895427B2 (en) 2009-01-06 2018-02-20 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9107419B2 (en) 2009-01-06 2015-08-18 Curelon Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
JP2012514602A (en) * 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー Compositions and methods for eradication or reduction of Staphylococcus aureus which are in the compositions and methods as well as on the surface for the treatment or prevention of Staphylococcus aureus infection
US9415014B2 (en) 2009-04-13 2016-08-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9931302B2 (en) 2009-04-13 2018-04-03 Curemark , LLC Enzyme delivery systems and methods of preparation and use
US10098844B2 (en) 2009-04-13 2018-10-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US9492515B2 (en) 2011-04-21 2016-11-15 Curemark, Llc Method of treatment of schizophreniform disorder
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia

Similar Documents

Publication Publication Date Title
Haas Disinfection
TWI286078B (en) Effervescent cleansing cosmetic article
NO983214A (en) Cleaning and sanitiseringsblanding
CA2384648A1 (en) Transparent cleansing composition
MY131167A (en) Granular fabric softener compositions which form aqueous emulsion concentrates
MXPA04005637A (en) Cellulose fibers treated with acidic odor control agents.
MX9707482A (en) Skin care products containing anti-itching/anti-irritant agents.
CA2407098A1 (en) Antimicrobial composition
MA22320A1 (en) Composition for personal grooming and cleaning
AR011428A1 (en) Personal cleansing composition in the form of a stable aqueous emulsion
JPS57186733A (en) Agent for use in contact lenses
CA2351925A1 (en) Cleansing compositions
JPH04243812A (en) Shampoo composition
AR025258A1 (en) Rinsable composition antimicrobial purification and methods for reducing the amount of germs on the skin and to treat acne.
MXPA02000063A (en) Aqueous liquid detergent compositions comprising an effervescent system.
CA2304669A1 (en) Acidic, thickened cleaning and disinfecting compositions
ES2148239T3 (en) Agent slightly alkaline dishwasher.
CA2472092A1 (en) A method of conditioning fabrics in a tumble dryer
CA2411373A1 (en) Stable liquid enzyme compositions with enhanced activity
CA2102432A1 (en) Divalent Silver Oxide Bactericides
MXPA02000282A (en) Personal care compositions.
CA2127660A1 (en) High foaming nonionic surfactant based liquid detergent
MXPA03000391A (en) Self foaming cleansing gel.
BG63612B1 (en) Composition and method for the prevention and treatment of hiv and other human infectious diseases
MX9705165A (en) Stabilization of liquid enzyme compositions.